ARDX - Ardelyx Inc. - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

667.7M

Cash

127.6M

Avg Qtr Burn

-17.67M

Short % of Float

11.43%

Insider Ownership

1.74%

Institutional Own.

56.10%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
XPHOZAH (Tenapanor) (Phosphate Absorption Inhibitor) Details Electrolyte disorder, Hyperphosphatemia, Kidney disease, Chronic kidney disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tenapanor (Ibsrela) (NHE3 sodium transport inhibitor) Details Irritable bowel syndrome, Constipation	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RDX013 Details Hyperkalemia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.